Comparing Spectral AI (MDAI) & The Competition

Spectral AI (NASDAQ:MDAIGet Free Report) is one of 229 public companies in the “Surgical & medical instruments” industry, but how does it compare to its competitors? We will compare Spectral AI to similar companies based on the strength of its analyst recommendations, earnings, profitability, dividends, institutional ownership, valuation and risk.

Analyst Recommendations

This is a summary of recent ratings and target prices for Spectral AI and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spectral AI 0 0 3 1 3.25
Spectral AI Competitors 1802 4763 8841 259 2.48

Spectral AI presently has a consensus price target of $4.50, indicating a potential upside of 188.46%. As a group, “Surgical & medical instruments” companies have a potential upside of 19.42%. Given Spectral AI’s stronger consensus rating and higher possible upside, analysts plainly believe Spectral AI is more favorable than its competitors.

Valuation & Earnings

This table compares Spectral AI and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Spectral AI $22.53 million -$20.85 million -1.16
Spectral AI Competitors $1.07 billion $10.77 million -7.71

Spectral AI’s competitors have higher revenue and earnings than Spectral AI. Spectral AI is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

67.1% of Spectral AI shares are owned by institutional investors. Comparatively, 48.0% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 56.7% of Spectral AI shares are owned by company insiders. Comparatively, 15.6% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Spectral AI and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Spectral AI -89.85% N/A -104.64%
Spectral AI Competitors -563.95% -136.63% -25.35%

Volatility and Risk

Spectral AI has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, Spectral AI’s competitors have a beta of 0.52, indicating that their average share price is 48% less volatile than the S&P 500.

Summary

Spectral AI beats its competitors on 10 of the 13 factors compared.

About Spectral AI

(Get Free Report)

Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.

Receive News & Ratings for Spectral AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral AI and related companies with MarketBeat.com's FREE daily email newsletter.